Biofrontera Inc.
BFRIHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. With a market capitalization of $23.9M, it sits in micro-cap territory. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Market Cap
$23.9M
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
3.74
EPS (TTM)
$-0.43
EPS (Fwd)
$0.43
ROE
-988.4%
ROA
-17.4%
Cash
$4.7M
Total Debt
$7.5M
Free CF
-$7.6M
52W Change
87.6%
Annual Financials
Cash vs Debt
Where BFRI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BFRI finished 47.57% above its 150-day moving average ($1.03) and 56.70% above its 200-day moving average ($0.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BFRI overbought or oversold?
At the September 3, 2026 close, BFRI's RSI(14) was 72.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Biofrontera Inc. carries $7.5M in total debt against $4.7M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$7.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -988.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $28.7M (2022) to $41.7M (2025), reflecting a 45% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BFRI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.